XJPX
7733
Market cap11bUSD
Jul 09, Last price
1,741.00JPY
1D
-1.64%
1Q
11.00%
Jan 2017
72.38%
Name
Olympus Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Tokyo, Japan, in 1919, Olympus Corporation is a global leader in the manufacturing and distribution of advanced precision machinery and scientific instruments. The company structures its diverse operations into four main segments. Its Endoscopic Solutions division provides sophisticated endoscopic tools for gastrointestinal and surgical procedures, along with complete endoscopy systems and crucial repair services. The Therapeutic Solutions segment delivers specialized medical devices for urology, gynecology, and otolaryngology (ear, nose, and throat), alongside endo-therapy and energy-based devices, and single-use surgical instruments. Under its Scientific Solutions umbrella, Olympus supplies an array of biological and industrial microscopes, industrial inspection equipment including endoscopes and videoscopes, non-destructive testing apparatus, and X-ray fluorescence (XRF) analyzers. The "Others" category encompasses biomedical materials and orthopedic equipment. Furthermore, Olympus's extensive offerings include additional medical technologies such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, supported by system integration and comprehensive maintenance and service programs. The company, which was originally known as Olympus Optical Co., Ltd., officially rebranded as Olympus Corporation in October 2003.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||